ClinicalTrials.gg
CompletedNCT01768117B1971042Updated Dec 20, 2018Results posted

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

A Phase 2 interventional study of rLP2086 in Meningitis, Meningococcal, Serogroup B, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-20.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningitis, Meningococcal.

Enrollment
11th of 11
13 · median 250
Started
2013
the only one that year
Phase 2
3 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Pfizer

Among the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, this one is the 11th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 2, and was the 6th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

1 of the 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About 4CMenB vaccine

4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing 4CMenB vaccine in Meningitis, Meningococcal, or all of them as a file.
02

Study summary

This study will assess the safety, tolerability and immunogenicity of bivalent rLP2086 vaccine in laboratory workers ≥18 to ≤65 years of age administered on a Month 0, 2, and 6 schedule. The study will recruit laboratory personnel (inclusive of Pfizer staff) who work directly with pathogenic Neisseria meningitidis in the context of the bivalent rLP2086 vaccine development program. The study will provide descriptive safety and immunogenicity data following vaccination of these individuals with bivalent rLP2086 vaccine.

03

Conditions studied

  • Meningitis, Meningococcal, Serogroup B
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Laboratory personnel (inclusive of Pfizer staff) who work directly with pathogenic Neisseria meningitidis in the context of the bivalent rLP2086 vaccine development program.
  2. Male or female subject aged ≥18 to ≤65 years at the time of enrollment.
  3. Negative urine pregnancy test.

Exclusion criteria

Exclusion Criteria:

  1. Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.
  2. A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function or those receiving therapy. Subjects with terminal complement deficiency are excluded from participation in this study.
  3. Significant neurological disorder or history of seizure (excluding simple febrile seizure).
  4. Current chronic use of systemic antibiotics.
  5. Received any drugs, vaccines, or devices within 28 days before administration of the first study vaccination.
  6. Any neuroinflammatory or condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
  7. Prior receipt of any vaccine specifically targeting fHBP or LP2086 antigens.
  8. History of microbiologically proven disease caused by Neisseria meningitidis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    rLP2086

    Biological: rLP2086

Interventions

  • BiologicalrLP2086

    Drug pages: MenB-FHbp vaccine · 4CMenB vaccine

    0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ)

    Time frame: 1 month after vaccination 3

  2. Percentage of Participants With at Least One Adverse Event (AE)

    Time frame: Vaccination 1 up to 1 month after Vaccination 3

Secondary outcomes

  1. Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= LLOQ

    Time frame: 1 month after vaccination (Vac) 1, 2, Immediately prior to vaccination 3

  2. Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= LLOQ For All 4 Primary Test Strains Combined

    Time frame: 1 month after vaccination 3

  3. Number of Participants With 4-fold Increase in Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level

    Time frame: 1 month after vaccination 3

07

Results

Posted Mar 9, 2015
Limitations and caveats
Results of immunogenicity endpoints were reported in ''number'' and not in ''proportion'' as per team's input.

Participant flow

Participant flow — Overall Study
MilestonerLP2086
Started13
Completed7
Not completed6
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject2
Withdrew: Protocol violation3

Outcome measures

PrimaryNumber of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ)
Time frame:
1 month after vaccination 3
Reported as:
Number · participants
Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ)
participantsrLP2086
PMB80 [A22] 1:16 (N=6)6 (54.1 to 100.0)
PMB2001 [A56] 1:8 (N=5)5 (47.8 to 100.0)
PMB2948 [B24] 1:8 (N=6)6 (54.1 to 100)
PMB2707 [B44] 1:8 (N=6)3 (11.8 to 88.2)
PrimaryPercentage of Participants With at Least One Adverse Event (AE)
Time frame:
Vaccination 1 up to 1 month after Vaccination 3
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event (AE)
percentage of participantsrLP2086
Percentage of Participants With at Least One Adverse Event (AE)46.2
SecondaryNumber of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= LLOQ
Time frame:
1 month after vaccination (Vac) 1, 2, Immediately prior to vaccination 3
Reported as:
Number · participants
Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= LLOQ
participantsrLP2086
1 month after Vac 1: PMB80 [A22] 1:16 (N=6)3 (11.8 to 88.2)
1 month after Vac 2: PMB80 [A22] 1:16 (N=5)3 (22.3 to 95.7)
Immediately prior to Vac 3: PMB80 [A22] 1:16 (N=6)4 (54.1 to 100.0)
1 month after Vac 1: PMB2001 [A56] 1:8 (N=6)4 (4.3 to 77.7)
1 month after Vac 2: PMB2001 [A56] 1:8 (N=6)6
Immediately prior to Vac 3: PMB2001 [A56] 1:8(N=6)4
1 month after Vac 1: PMB2948 [B24] 1:8 (N=6)6
1 month after Vac 2: PMB2948 [B24] 1:8 (N=6)6
Immediately prior to Vac 3: PMB2948 [B24] 1:8(N=6)5
1 month after Vac 1: PMB2707 [B44] 1:8 (N=6)2
1 month after Vac 2: PMB2707 [B44] 1:8 (N=6)3
Immediately prior to Vac 3: PMB2707 [B44] 1:8(N=6)2
SecondaryNumber of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= LLOQ For All 4 Primary Test Strains Combined
Time frame:
1 month after vaccination 3
Reported as:
Number · participants
Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= LLOQ For All 4 Primary Test Strains Combined
participantsrLP2086
Number of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= LLOQ For All 4 Primary Test Strains Combined3 (14.7 to 94.7)
SecondaryNumber of Participants With 4-fold Increase in Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level
Time frame:
1 month after vaccination 3
Reported as:
Number · participants
Number of Participants With 4-fold Increase in Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level
participantsrLP2086
PMB80 [A22] (N=6)5 (35.9 to 99.6)
PMB2001 [A56] (N=5)5 (47.8 to 100.0)
PMB2948 [B24] (N=6)4 (22.3 to 95.7)
PMB2707 [B44] (N=6)3 (11.8 to 88.2)

Adverse events

Collected over AE reported from Vaccination 1 to 1 month after last administration of investigational product (bivalent rLP2086). SAE reported from Vaccination 1 to 6 months after last administration of investigational product (bivalent rLP2086). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rLP2086—0/13 (0%)6/13 (46.2%)
Most frequent other events
Most frequent other events
EventrLP2086
Gouty arthritisMusculoskeletal and connective tissue disorders1/7
Eye PainEye disorders1/13
Respiratory tract infection viralInfections and infestations1/13
Urinary tract infectionInfections and infestations1/13
Upper respiratory tract infectionInfections and infestations1/13
PresyncopeNervous system disorders1/13
ChillsGeneral disorders1/13

Baseline characteristics

Age, Customized
Age, Customized(participants)rLP2086
18- 40 years5
Greater than (>) 40 years8
Sex: Female, Male
Sex: Female, Male(Participants)rLP2086
Female9
Male4
08

Study locations

1 site
  • Frontage Clinical Services (Formally ABR)
    Hackensack, New Jersey 07601, United States
09

References and documents

Publications

  • Beeslaar J, Mather S, Absalon J, Eiden JJ, York LJ, Crowther G, Maansson R, Maguire JD, Peyrani P, Perez JL. Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine. 2022 Mar 15;40(12):1872-1878. doi: 10.1016/j.vaccine.2022.01.046. Epub 2022 Feb 11. PubMed 35164991 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2013
First posted
Jan 15, 2013
Start
Feb 2013
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Mar 9, 2015
Last update
Dec 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01768117
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 15, 2013
Start date
Feb 2013
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Mar 9, 2015
Last update
Dec 20, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MenB-FHbp vaccine · 4CMenB vaccine

Start the discussion